A local outbreak of iatrogenic botulism associated with cosmetic injections of botulinum neurotoxin-containing products, England, 2025.
Summary
An outbreak investigation in North East England identified 25 iatrogenic botulism cases linked to cosmetic botulinum injections. Case-control analysis implicated two practitioners and an unlicensed product with mislabeled potency (370 vs 200 units/vial), underscoring urgent regulatory and pharmacovigilance needs.
Key Findings
- 25 iatrogenic botulism cases occurred after cosmetic botulinum injections in North East England (June 2025).
- Case-control analysis associated cases with two practitioners and unlicensed products (p<0.001).
- Seized product testing found actual potency of 370 units/vial vs labeled 200 units/vial, indicating mislabeling and increased risk.
Clinical Implications
Clinicians should suspect iatrogenic botulism in patients with recent cosmetic injections presenting with bulbar or autonomic symptoms, verify use of licensed products, report adverse events, and coordinate with public health. Procurement should avoid unlicensed products; counseling on risks is essential.
Why It Matters
Provides actionable epidemiologic evidence linking unlicensed cosmetic neurotoxin products to severe morbidity, with laboratory confirmation of potency discrepancies. Likely to influence regulation, clinical vigilance, and procurement practices.
Limitations
- Single-region outbreak with small case numbers limits generalizability.
- Control sample size and selection not fully detailed; potential recall and selection biases.
Future Directions
Implement standardized potency testing, traceability, and licensing verification; enhance adverse event reporting and surveillance; evaluate educational interventions for practitioners and consumers.
Study Information
- Study Type
- Case-control
- Research Domain
- Prevention
- Evidence Level
- III - Observational analytic study identifying associations between exposures and outcomes
- Study Design
- OTHER